{"groups":[{"description":"2.5 mg by mouth (PO) daily","id":"FG000","title":"Letrozole"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Not Eligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"16"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Study terminated early due to slow patient accrual.","recruitmentDetails":"Recruitment Period: 09/24/03 through 01/30/08. All participants recruited at UT MD Anderson Cancer Center."}